Adocia Strengthens its Diabetic Foot Ulcer Patent Portfolio
News Jan 16, 2014
Adocia has announced that it has been granted two patents. The first patent is granted in Japan for the BioChaperone PDGF composition and the second in the United States for the BioChaperone polymer. Both patents will protect Adocia’s findings in the field of chronic wound healing, especially for diabetic foot ulcers.
The BioChaperone PDGF product has been successfully tested in a phase II clinical trial in India for the treatment of diabetic foot ulcers. This product is protected by two families of patents.
The first one covers the complexes between BioChaperone polymers and PDGF; the second covers BioChaperone polymers.
The patent on the complexes was granted in Europe and the United States in 2012 (cf. press release of June 13, 2012). The inclusion of Japan now extends the coverage to 29 countries.
Twenty-three are in Europe and the rest are the United States, Australia, Mexico, Russia and South Africa. This patent provides protection until September 26, 2026.
The BioChaperone polymers, a proprietary technology specifically developed by Adocia, are covered by the second patent. The US Patent and Trademark Office (USPTO) recently granted this patent.
Protection of these BioChaperone polymers is now established in the United States, Australia, China, Russia, France and South Africa. It is valid until September 26, 2027.
“We are very pleased with the positive outcome on two of our strategic patent families, especially because they have been granted by the very demanding national American and Japanese patent offices. Our product for treating diabetic foot ulcer is patent protected until at least 2026,” said Remi Soula, director of business development and intellectual property at Adocia. “The granting of these patents consolidates our strong portfolio of 22 patent families, of which six have been granted US patents.”
“We are actively pursuing the clinical development of the BioChaperone PDGF product for the treatment of diabetic foot ulcer. These patents cover the major markets we are targeting. Moreover, we hope to receive authorization to launch the phase III clinical trial in India very soon,” said Olivier Soula, delegate general director and R&D director.
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B TreatmentNews
All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.READ MORE
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE